Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2022
2021
2020
2019

2021.05.19

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

2021.04.13

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

2021.03.31

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

2021.03.29

Adagene Announces Clinical Advancement for ADG116

2021.03.16

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

Pagination

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Next page
Last page

Displaying 36 - 40 of 53

Shareholder Tools

© 2022 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn